Dofetilide use is not associated with increased mortality in patients with left ventricular hypertrophy and atrial fibrillation. (Record no. 41)

MARC details
000 -LEADER
fixed length control field 03071nam a22003737a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 221213s20222022 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1045-3873
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1111/jce.15733 [doi]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 36335642
245 ## - TITLE STATEMENT
Title Dofetilide use is not associated with increased mortality in patients with left ventricular hypertrophy and atrial fibrillation.
251 ## - Source
Source Journal of Cardiovascular Electrophysiology. 2022 Nov 06
252 ## - Abbreviated Source
Abbreviated source J Cardiovasc Electrophysiol. 2022 Nov 06
253 ## - Journal Name
Journal name Journal of cardiovascular electrophysiology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2022
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2023
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2022 Nov 06
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status aheadofprint
266 ## - Date added to catalog
Date added to catalog 2022-12-13
501 ## - WITH NOTE
Local holdings Available online through MWHC library: 2007 -2010, Available in print through MWHC library: 1999 - 2006
520 ## - SUMMARY, ETC.
Abstract BACKGROUND: Left ventricular hypertrophy (LVH) is common in patients with atrial fibrillation (AF), however, many antiarrhythmic drugs (AADs) are contraindicated. US guidelines recommend avoiding pure class III antiarrhythmics such as dofetilide in patients with significant LVH due to concern for an increased risk of death, however, clinical data is lacking. We sought to determine if dofetilide use was associated with increased mortality in patients with LVH.
520 ## - SUMMARY, ETC.
Abstract CONCLUSIONS: In a propensity-matched cohort of 718 patients with AF and LVH, dofetilide was not associated with increased mortality at 3 years. Our study adds to prior data demonstrating the safety of dofetilide in this population despite guideline recommendations against its use. Given the limited options for AF management in LVH patients, dofetilide may be reasonable for symptomatic AF management. Copyright © 2022 Wiley Periodicals LLC.
520 ## - SUMMARY, ETC.
Abstract METHODS: Patients >=18 years of age with AF and LVH >= 1.4 cm were included. A group of patients treated with dofetilide and a control group of patients without a history of AAD use were propensity matched. The primary outcome was all-cause mortality at 3 years and secondary outcomes were total number of all-cause hospitalizations and hospitalizations related to AF.
520 ## - SUMMARY, ETC.
Abstract RESULTS: There were 359 patients in each of the groups. Baseline variables were well-matched. The primary outcome of all-cause mortality occurred in 7% of patients in the dofetilide group and 12% of patients in the control group (hazard ratio: 0.90, 95% confidence interval: 0.53-1.53). Total all-cause hospitalizations were higher in the control group but hospitalizations for AF were no different.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Medicine/Internal Medicine
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Mehdi, Noor-Ul-Huda A
Institution Code MWHC
790 ## - Authors
All authors and other members of the UPMC Study Group, Bhonsale A, Estes NM, Jain SK, Medoff BS, Mehdi NA, Mulukutla S, Saba S, Sezer A, Thoma FW, Wann DG
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1111/jce.15733">https://dx.doi.org/10.1111/jce.15733</a>
Public note https://dx.doi.org/10.1111/jce.15733
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 12/13/2022   36335642 36335642 12/13/2022 12/13/2022 Journal Article

Powered by Koha